BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
Go back to BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.75 +0.85 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.90 | 52 Week High | $108.96 | |||
| Open | $55.80 | 52 Week Low | $62.12 | |||
| Day High | $57.00 | P/E | N/A | |||
| Day Low | $55.74 | EPS | $-1.27 | |||
| Volume | 698,498 | |||||
